Hematology· Topic 6.2 Anemia from hemolysis and abnormal hemoglobin· 6.2.13

Sickle cell disease

Sickle cell disease is an autosomal recessive hemoglobinopathy caused by a beta-globin point mutation that produces hemoglobin S, which polymerizes under deoxygenation to sickle erythrocytes and drive chronic hemolysis and vaso-occlusion. Diagnosis is confirmed by hemoglobin electrophoresis or HPLC showing predominant HbS, and lifelong management centers on hydroxyurea, folic acid, penicillin prophylaxis and vaccination for functional asplenia, transcranial Doppler stroke screening, and, in severe disease, transfusion, hematopoietic stem cell transplant, or gene therapy.

7 min read3 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy from homozygosity (or compound heterozygosity) for hemoglobin S, an abnormal beta-globin that polymerizes under…

  • Epidemiology

    Predominantly affects patients of African descent: in the United States sickle hemoglobin is far more common among Black persons, with sickle cell trait present in roughly 8% of Black Americans.

  • Risk factors

    Family history and ancestry from a historically malaria-endemic region: SCD requires inheritance of a sickle allele from both parents.

  • Pathophysiology

    The causal mutation: a point mutation in the beta-globin gene substitutes valine for glutamate at position 6, producing hemoglobin S.

  • Clinical features

    Chronic hemolytic anemia: pallor, fatigue, jaundice, and scleral icterus from ongoing hemolysis, present from early childhood in Hb SS disease.

  • Differential diagnosis

    Hereditary spherocytosis: hemolytic anemia with jaundice and splenomegaly, but spherocytes rather than sickle cells, a positive osmotic fragility/EMA-binding test, and a negative Coombs test.

  • Diagnosis

    Confirm with hemoglobin electrophoresis or HPLC: the diagnostic test, showing a predominant hemoglobin S band.

  • Management

    Confirm the genotype and establish baseline care: hemoglobin electrophoresis, baseline CBC, reticulocyte count, hemolysis labs, and enrollment in a comprehensive sickle cell program.

  • Complications

    Acute chest syndrome: the leading cause of death in SCD, from vaso-occlusion in the pulmonary vasculature; covered in detail in sickle cell disease complications.

  • Prognosis

    Survival has improved dramatically with newborn screening, prophylaxis, and hydroxyurea, with many patients now living into middle adulthood or beyond, though median survival remains reduced.

  • Prevention

    Universal folic acid 1 mg PO once daily in all patients to prevent folate-deficient megaloblastic change on top of chronic hemolysis.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.